Skip to main content Skip to search Skip to main navigation

Swissmedic: Amendment to GMP Compliance by Foreign Manufacturers

Swissmedic has updated its guidance on Good Manufacturing Practice (GMP) compliance for foreign manufacturers, clarifying documentation requirements for various application types (e.g., new authorizations, type IA/IB/II changes for human and veterinary medicines).

To prove GMP compliance, documents must be provided by the Responsible Person (RP). Preferably, these should be certificates from authorities with GMP systems recognized as equivalent to Switzerland’s. If such certificates are unavailable, audit reports may be accepted under specific conditions.

Key Clarifications on Audit Reports:

  • The approved audit report should be submitted with the application. Manufacturer approval depends on this report.
  • Re-audit reports with reduced scope are accepted if missing details are addressed through an RP assessment or a RP summary based on the original complete audit covering the missing points.
  • Redacted documents (report/CAPA plan) are allowed if the assessment is not compromised.
  • Audit reports must be no older than three years and must cover the relevant product.

Inspection Reports:

Reports from recognized authorities are accepted if:

  • Not older than three years,
  • The inspection was conducted on-site, 
  • Relevant to the product in question.

Veterinary Medicines:

For notifications under Art. 39 VAZV, one copy of the GMP certificate or manufacturing authorization per foreign manufacturer is sufficient. If unavailable, an RP-prepared risk assessment may be submitted instead. Swissmedic provides guidance on the required content to ensure it proves GMP compliance.

The updated guidance took effect on 1 May 2025.


Source:

Swissmedic: General communications


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
What are the requirements for gas distribution systems?

What are the requirements for gas distribution systems?

You can view the answer here:
Read more
What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
Previous
Next